Unlocking the Potential of DCX(DCAF15) E3 Protein Ligase Complex as a Drug Target or Biomarker
Unlocking the Potential of DCX(DCAF15) E3 Protein Ligase Complex as a Drug Target or Biomarker
Introduction
The protein ligase complex (PLC) is a ubiquitous molecular machine that plays a crucial role in various cellular processes, including DNA replication, gene expression, and intracellular signaling. One of the best-known protein ligases in the PLC is the DCX(DCAF15) complex, which is expressed in various tissues and plays a key role in the regulation of DNA double-strand break repair. DCX(DCAF15) complex is composed of several subunits, including DCX, DCAF15, and other non-canonical RNA-binding proteins ( ncRNPs), which work together to recognize and repair double-strand breaks in damaged DNA.
TheDCX(DCAF15) complex is an essential component of the cellular response to DNA damage, as it ensures the timely repair of damaged DNA by promoting the formation of a stable double-strand break. DCX(DCAF15) complex has been implicated in various cellular processes , including cell growth, apoptosis, and transcriptional regulation. The study of DCX(DCAF15) complex and its role in cellular processes has become an increasingly important area of 鈥嬧?媟esearch, with potential implications for the development of new therapeutic strategies.
Drug Targets and Biomarkers
The DCX(DCAF15) complex is a promising drug target and a potential biomarker for various diseases, including cancer. The DCX protein has been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. DCX(DCAF15) complex has also been associated with the regulation of cellular signaling pathways, including T cell development and cancer progression.
One of the key advantages of targeting the DCX(DCAF15) complex is its potential to disrupt multiple cellular processes that are associated with cancer development. For example, the DCX(DCAF15) complex has been shown to regulate the entry of cancer cells into the bloodstream , which could be a potential target for anti-cancer drugs that aim to limit cancer cell spread. Additionally, the DCX(DCAF15) complex has been linked to the regulation of cell cycle progression, which is a critical step in cancer cell growth and development.
Another promising aspect of targeting the DCX(DCAF15) complex is its potential to serve as a biomarker for cancer diagnosis and treatment. The DCX(DCAF15) complex is expressed in various tissues, including the bloodstream, and has been shown to be involved in the regulation of cellular processes that are critical for cancer development. Therefore, measuring the levels of DCX(DCAF15) complex in cancer cells or body fluids could be a potential biomarker for cancer diagnosis or treatment.
Understanding the DCX(DCAF15) complex
The DCX(DCAF15) complex is a highly conserved protein complex that is found in various organisms, including bacteria, archaea, and eukaryotes. The complex is composed of several subunits, including DCX, DCAF15, and other ncRNPs, which work together to recognize and repair double-strand breaks in damaged DNA.
The DCX protein is a 21 kDa protein that is expressed in various tissues, including the nucleus, mitochondria, and cytoplasm. It plays a key role in the regulation of DNA double-strand break repair and is a component of the DNA damage response pathway. DCX has been shown to interact with various DNA-binding proteins, including the Ku70 protein, which is involved in the repair of double-strand breaks.
The DCAF15 protein is a 19 kDa protein that is also expressed in various tissues. It is involved in
Protein Name: DCX(DCAF15) E3 Protein Ligase Complex
The "DCX(DCAF15) E3 protein ligase complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCX(DCAF15) E3 protein ligase complex comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A
